Want to see HK:0775 full AI Analyst Report?
Top Page
CK Life Sciences International (Holdings), Inc.
(0775)
Select Model
Select Model
Rating:40Underperform
Price Target:
HK$0.57
▼(-31.33% Downside)
Action:Downgraded
Date:08/21/26
The score is held down primarily by deteriorating financial performance—sharp margin compression, deeper losses, and a swing to negative operating and free cash flow—combined with elevated leverage. Technicals are only mildly supportive with short-term improvement but a weak longer-term trend and negative MACD. Valuation remains unattractive/unclear due to negative earnings and no dividend yield provided.
Positive Factors
Diversified life-sciences platform
A portfolio spanning agriculture and environmental applications, supported by in-house R&D and multiple-market subsidiaries, provides diversification and creates durable opportunities to commercialize biological and biotechnology solutions.
Negative Factors
Severe margin and profitability deterioration
The sharp margin contraction and move into operating losses weaken earnings quality and suggest pressure from costs, pricing or product mix. Sustained losses could restrict investment capacity and delay recovery in shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified life-sciences platform
A portfolio spanning agriculture and environmental applications, supported by in-house R&D and multiple-market subsidiaries, provides diversification and creates durable opportunities to commercialize biological and biotechnology solutions.
Read all positive factors
CK Life Sciences International (Holdings), Inc. (0775) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.48B
Dividend Yield1.01%
Average Volume (3M)6.30M
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue Growth0.50%
EPS Growth76.90%
CountryHK
Employees1,920
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding9,611,072,000
10 Day Avg. Volume9,599,608
30 Day Avg. Volume6,297,573
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)2.09
Price to Sales (P/S)1.46
P/FCF Ratio-28.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model
Company Description
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmac...
How the Company Makes Money
null...
CK Life Sciences International (Holdings), Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
43
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.52B | 5.41B | 5.52B | 5.32B | 5.28B | 5.40B |
| Gross Profit | 739.27M | 785.38M | 1.69B | 1.64B | 1.63B | 1.63B |
| EBITDA | 76.28M | -49.42M | 337.27M | 624.75M | 469.51M | 449.14M |
| Net Income | -66.34M | -188.45M | -126.55M | 17.25M | 131.96M | 162.80M |
Balance Sheet | ||||||
| Total Assets | 12.16B | 11.84B | 10.79B | 11.25B | 11.27B | 11.73B |
| Cash, Cash Equivalents and Short-Term Investments | 535.65M | 603.07M | 571.21M | 676.16M | 704.13M | 902.47M |
| Total Debt | 6.83B | 6.62B | 6.10B | 5.93B | 5.95B | 6.21B |
| Total Liabilities | 8.07B | 7.99B | 7.28B | 7.06B | 7.11B | 7.23B |
| Stockholders Equity | 3.95B | 3.78B | 3.51B | 4.19B | 4.16B | 4.50B |
Cash Flow | ||||||
| Free Cash Flow | -321.70M | -277.76M | 157.00M | 222.35M | 146.69M | 206.33M |
| Operating Cash Flow | -76.72M | -32.77M | 353.53M | 514.18M | 363.66M | 423.57M |
| Investing Cash Flow | -449.97M | -362.68M | -96.64M | -67.96M | -22.12M | -257.88M |
| Financing Cash Flow | 262.71M | 428.57M | -341.98M | -477.95M | -515.34M | -220.08M |
CK Life Sciences International (Holdings), Inc. Technical Analysis
Negative
0.83
Price Trends
0.58
Negative
0.64
Negative
0.73
Negative
Market Momentum
<0.01
Positive
45.44
Neutral
10.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Negative. The current price of 0.83 is above the 20-day moving average (MA) of 0.58, above the 50-day MA of 0.58, and above the 200-day MA of 0.73, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.44 is Neutral, neither overbought nor oversold. The STOCH value of 10.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0775.
CK Life Sciences International (Holdings), Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$29.74B | 16.31 | 16.54% | 1.78% | 27.24% | 79.48% | |
64 Neutral | HK$35.74B | 35.47 | 20.41% | ― | 32.63% | 8.87% | |
63 Neutral | HK$97.40B | 37.61 | 7.56% | 2.05% | 14.57% | -31.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$10.81B | -14.77 | -28.15% | ― | -59.39% | -130.04% | |
46 Neutral | HK$33.87B | -76.96 | -7.32% | ― | 34.83% | 58.94% | |
40 Underperform | HK$5.48B | -83.58 | -1.72% | 1.01% | 0.50% | 76.90% |
* Healthcare Sector Average
HK:0775
CK Life Sciences International (Holdings), Inc.
0.56
-0.34
-37.78%
HK:1177
Sino Biopharmaceutical
5.85
-2.84
-32.71%
HK:1672
Ascletis Pharma, Inc.
10.18
-3.97
-28.06%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.86
-18.98
-51.52%
HK:2096
Simcere Pharmaceutical Group Limited
11.63
-2.02
-14.79%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
65.90
-20.00
-23.28%
CK Life Sciences International (Holdings), Inc. Corporate Events
CK Life Sciences Narrows Loss as Reorganised R&D Pipeline Advances in Oncology and Pain
Aug 11, 2026
CK Life Sciences reported an unaudited loss attributable to shareholders of HK$28.7 million for the first half of 2026, an 81% year-on-year reduction driven largely by a post-reorganisation change in accounting for RD expenses. Following the sale ...
CK Life Sciences Sets August Board Meeting to Approve Interim Results and Dividend
Jul 30, 2026
CK Life Sciences International (Holdings) Inc. has scheduled a board meeting in Hong Kong on 11 August 2026 to review and approve the group’s interim results for the six months ended 30 June 2026. The board will also consider the payment of ...
CK Life Sciences Shareholders Back All AGM Resolutions, Renew Mandates
May 21, 2026
Shareholders of CK Life Sciences International (Holdings) Inc. overwhelmingly approved all resolutions at the annual general meeting held on 21 May 2026, including the receipt of the 2025 audited financial statements. The strong backing signals co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.